Biotechnology News and Research

RSS

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington’s patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington’s often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.

12 Sep 2011

Publix to offer Bioject ZetaJet for flu immunizations

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, announced today that beginning in September 2011, select Publix Super Markets (Publix) in the Southeast region will be offering flu season immunizations utilizing the Bioject ZetaJet™. Publix will be conducting evaluations in 52 stores in Florida, Georgia, Alabama and South Carolina.

12 Sep 2011

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

12 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

Chromatin, Dow AgroSciences achieve first milestone in research collaboration

Chromatin Inc. announced today that they have reached the first milestone in their research collaboration with Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company. This collaboration is focused on developing a novel combination of Chromatin's Mini-Chromosomes with Dow AgroSciences' EXZACT Precision Technology.

12 Sep 2011

Bruker to acquire Center for Tribology

Bruker Corporation today announced the signing of a purchase agreement to acquire Center for Tribology, Inc. (CETR) for an undisclosed amount.

12 Sep 2011

InterMune to launch Esbriet for German patients with IPF

InterMune, Inc. today announced that Esbriet will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available in Europe since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease.

12 Sep 2011

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

12 Sep 2011

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy.

12 Sep 2011

Chronic pain gene discovered

Scientists have found the gene responsible for chronic pain. It said that this could lead to drugs for treating long-lasting back pain.

12 Sep 2011

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

12 Sep 2011

PharmAthene completes 1,500 liter engineering production run for SparVax anthrax vaccine

PharmAthene, Inc. announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax.

12 Sep 2011

UMSOM to receive FDA approval for whole parasite malaria vaccine clinical trials

For the first time, a malaria vaccine that uses the entire malaria parasite has proven safe and shown promise to produce a strong immune response in a clinical trial, according to a new study co-authored by researchers at the University of Maryland School of Medicine Center for Vaccine Development.

12 Sep 2011

Patheon third quarter revenues increase 5.8% to $172.7 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today: Details of Patheon's new corporate strategy, including an initial heavy focus on strengthening the company's core operations.

9 Sep 2011

Mary Ann Liebert launches Games for Health Industry Insider

Mary Ann Liebert, Inc., publishers announces the launch of Games for Health Industry Insider , a new bi-weekly electronic newsletter offering up-to-the-minute industry news on health games-an emerging and increasingly adopted resource for healthcare.

9 Sep 2011

Maxygen increases stock repurchase program to $20 million

Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.

8 Sep 2011

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that positive data from a retrospective commercial patient chart review of XIAFLEX (collagenase clostridium histolyticum) used for the treatment of adult Dupuytren's contracture patients with a palpable cord are available via e-posters at the American Society for Surgery of the Hand meeting in Las Vegas.

8 Sep 2011

Dysregulated neuronal RNA transport may cause Fragile X-associated tremor/ataxia syndrome

SUNY Downstate scientist Ilham Muslimov, MD, PhD, along with senior author Henri Tiedge, PhD, professor of physiology and pharmacology and of neurology, published a study suggesting that cellular dysregulation associated with certain neurodegenerative disorders may result from molecular competition in neuronal RNA transport pathways.

8 Sep 2011

Pall inaugurates new Singapore Life Sciences Centre of Excellence

Pall Corporation, a global leader in filtration, separation and purification, today inaugurated its Pall Life Sciences Centre of Excellence in Singapore, the latest addition to the company's global customer support network.

From Pall Corporation 8 Sep 2011

Biotechnology News and Research

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

Publix to offer Bioject ZetaJet for flu immunizations

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

Chromatin, Dow AgroSciences achieve first milestone in research collaboration

Bruker to acquire Center for Tribology

InterMune to launch Esbriet for German patients with IPF

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Chronic pain gene discovered

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

PharmAthene completes 1,500 liter engineering production run for SparVax anthrax vaccine

UMSOM to receive FDA approval for whole parasite malaria vaccine clinical trials

Patheon third quarter revenues increase 5.8% to $172.7 million

Mary Ann Liebert launches Games for Health Industry Insider

Maxygen increases stock repurchase program to $20 million

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Dysregulated neuronal RNA transport may cause Fragile X-associated tremor/ataxia syndrome

Pall inaugurates new Singapore Life Sciences Centre of Excellence

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News